Can Fite BioPharma : Submits FDA with an IND Application to Conduct Phase IIb Clinical Trial of Namodenoson in MASH Patients -April 03, 2024 at 07:06 am EDT
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of...